Cvijic Christine Mikail 4
4 · Neurogene Inc. · Filed Jul 2, 2026
Research Summary
AI-generated summary of this filing
Neurogene (NGNE) President/CFO Christine Cvijic Sells Shares
What Happened
Christine Cvijic, President, Chief Financial Officer and a director of Neurogene Inc. (NGNE), sold a total of 4,800 shares in open-market transactions on July 1–2, 2026. The sales consisted of 739 shares at a weighted-average price of $34.06 ($25,170), 2,531 shares at $34.58 ($87,519), and 1,530 shares at $35.23 ($53,897), for aggregate proceeds of approximately $166,586. These were sales (not purchases) and therefore are generally routine dispositions rather than purchases signaling added insider conviction.
Key Details
- Transaction dates and reported amounts:
- 2026-07-01: 739 shares @ $34.06 — $25,170 (weighted avg; prices ranged $34.005–$34.095).
- 2026-07-02: 2,531 shares @ $34.58 — $87,519 (weighted avg; prices ranged $34.05–$34.99).
- 2026-07-02: 1,530 shares @ $35.23 — $53,897 (weighted avg; prices ranged $35.11–$35.255).
- Total sold: 4,800 shares for about $166,586.
- Shares held after the sales: 4,800 shares held jointly by Ms. Cvijic and her spouse (per filing).
- Notable footnotes:
- Transactions were executed pursuant to a 10b5-1 trading plan adopted August 18, 2025; sold shares were held jointly with spouse David Cvijic.
- Prices reported are weighted averages; the filer has offered to provide a breakdown of quantities at each individual price within the disclosed ranges upon request.
- The filing discloses outstanding restricted stock units: 10,635 (vest Mar 13, 2027), 13,533 (vest in installments Mar 26, 2027 & Mar 26, 2028), and 22,000 (vest in installments Feb 20, 2027–2029).
- Timeliness: Form 4 was filed on July 2, 2026 covering trades on July 1–2, 2026 (filed within the usual Form 4 reporting window).
Context
These were planned dispositions under a pre-established 10b5-1 plan (a common mechanism executives use to sell shares on a set schedule). Sales do not necessarily indicate a change in view about the company; purchases typically carry more informational weight. The filing is informational—retail investors may consider this alongside company fundamentals and broader insider activity.
Insider Transaction Report
- Sale
Common Stock
[F1][F2][F3]2026-07-01$34.06/sh−739$25,170→ 92,901 total - Sale
Common Stock
[F1][F4][F3]2026-07-02$34.58/sh−2,531$87,519→ 90,370 total - Sale
Common Stock
[F1][F5][F3]2026-07-02$35.23/sh−1,530$53,897→ 88,840 total
Footnotes (5)
- [F1]The transactions reported on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on August 18, 2025. Shares sold were held jointly by the reporting person and her spouse, David Cvijic.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.005 to $34.095, inclusive. The reporting person undertakes to provide Neurogene Inc. (the "Company"), any securityholder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Includes (a) 10,635 restricted stock units granted on March 13, 2024 that will vest on March 13, 2027; (b) 13,533 restricted stock units granted on March 26, 2025, which will vest annually in equal installments on March 26, 2027 and March 26, 2028; and (c) 22,000 restricted stock units granted on February 20, 2026, which will vest annually in equal installments on February 20, 2027, February 20, 2028 and February 20, 2029. Of the remaining shares, following completion of all sales reported pursuant to this Form 4, 4,800 are held jointly by the reporting person and her spouse, David Cvijic.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.05 to $34.99, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.11 to $35.255, inclusive. The reporting person undertakes to provide the Company, any securityholder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote